科學家發現新冠康複者擁有特別的T細胞 2003年薩斯康複者擁有這種T細胞

 

科學家對丅細胞的研究發現，link和文章如下，有興趣的可以讀讀。我稍稍總結了一下。

 

科學家發現新冠康複者擁有 SARS-CoV-2-specific T cells 。同時也發現2003年薩斯康複者，在17年後仍然擁有類似的memory T細胞，並顯示出對新冠的交叉免疫力。

 

科學家還發現，受測試的從未得過新冠的健康者，超過50%也具有新冠特有的T細胞 - SARS-CoV-2-specific T cells。科學家推測可能是因為這些人曾經exposed to其他類型的冠狀病毒而擁有了交叉免疫力，比如普通感冒或者末知的動物冠狀病毒。這可能解釋了為什麽有些人能更好的控製感染。

 

 

https://www.eurekalert.org/pub_releases/2020-07/dms-sus071620.php

 

Scientists uncover SARS-CoV-2-specific T cell immunity in recovered COVID-19 and SARS patients。

 

Singapore scientists uncover SARS-CoV-2-specific T cell immunity in recovered COVID-19 and SARS patients, and in uninfected individuals。

 

DUKE-NUS MEDICAL SCHOOL

 

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore General Hospital (SGH) and National Centre for Infectious Diseases (NCID) was published in Nature. 

 

The findings suggest infection and exposure to coronaviruses induces long-lasting memory T cells, which could help in the management of the current pandemic and in vaccine development against COVID-19.

 

The team tested subjects who recovered from COVID-19 and found the presence of SARS-CoV-2-specific T cells in all of them, which suggests that T cells play an important role in this infection. Importantly, the team showed that patients who recovered from SARS 17 years ago after the 2003 outbreak, still possess virus-specific memory T cells and displayed cross-immunity to SARS-CoV-2.

 

"Our team also tested uninfected healthy individuals and found SARS-CoV-2-specific T cells in more than 50 percent of them. This could be due to cross-reactive immunity obtained from exposure to other coronaviruses, such as those causing the common cold, or presently unknown animal coronaviruses. 

 

It is important to understand if this could explain why some individuals are able to better control the infection," said Professor Antonio Bertoletti, from Duke-NUS' Emerging Infectious Diseases (EID) programme, who is the corresponding author of this study.

Associate Professor Tan Yee Joo from the Department of Microbiology and Immunology at NUS Yong Loo Lin School of Medicine and Joint Senior Principal Investigator, Institute of Molecular and Cell Biology, A*STAR added, 

 

"We have also initiated follow-up studies on the COVID-19 recovered patients, to determine if their immunity as shown in their T cells persists over an extended period of time. This is very important for vaccine development and to answer the question about reinfection."

 

"While there have been many studies about SARS-CoV-2, there is still a lot we don't understand about the virus yet. What we do know is that T cells play an important role in the immune response against viral infections and should be assessed for their role in combating SARS-CoV-2, which has affected many people worldwide. Hopefully, our discovery will bring us a step closer to creating an effective vaccine," said Associate Professor Jenny Low, Senior Consultant, Department of Infectious Diseases, SGH, and Duke-NUS' EID programme.

 

"NCID was heartened by the tremendous support we received from many previous SARS patients for this study. Their contributions, 17 years after they were originally infected, helped us understand mechanisms for lasting immunity to SARS-like viruses, and their implications for developing better vaccines against COVID-19 and related viruses," said Dr Mark Chen I-Cheng, Head of the NCID Research Office.

 

The team will be conducting a larger study of exposed, uninfected subjects to examine whether T cells can protect against COVID-19 infection or alter the course of infection. They will also be exploring the potential therapeutic use of SARS-CoV-2-specific T cells.